In the race to supply vaccines to end the COVID-19 pandemic, U.S. drug developer Novavax turned to emerging Europe to speed up production with a pair of deals that endorsed a growing trend for consolidation in the region.
FOCUS-Big pharma and private equity seek healthy returns in Europe’s east
2021-05-20T06:03:35-04:00May 20th, 2021|
Related Posts
-
Worst-ever interviews: ‘They told us to crawl and moo’
May 3rd, 2024 -
Have the wheels come off for Tesla?
May 3rd, 2024 -
Is Palantir An Attractive AI Stock Buy Ahead Of Earnings
May 3rd, 2024